Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
36
NEUE Quote, Financials, Valuation and Earnings
Last price:
$7.44
Seasonality move
:
-24.69%
Day range:
$4.22 - $4.37
52-week range:
$3.79 - $16.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
--
Volume:
9.1K
Avg. volume:
9.2K
1-year change:
-18.06%
Market cap:
$35.7M
Revenue:
$1.2B
EPS (TTM):
-$51.16
Analysts' Opinion
-
Consensus RatingNeueHealth has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, NeueHealth has an estimated upside of 62.41% from its current price of $4.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $4.31.
Fair Value
-
According to the consensus of 0 analysts, NeueHealth has 62.41% upside to fair value with a price target of -- per share.
NEUE vs. S&P 500
-
Over the past 5 trading days, NeueHealth has underperformed the S&P 500 by -8.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeueHealth does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeueHealth revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter NeueHealth reported revenues of $232.9M.
Earnings Growth
-
NeueHealth has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NeueHealth reported earnings per share of -$8.51.
Enterprise value:
1.1B
EV / Invested capital:
-5.59x
Price / LTM sales:
0.04x
EV / EBIT:
--
EV / Revenue:
1.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$174.8M
Return On Assets:
-30.24%
Net Income Margin (TTM):
-36.28%
Return On Equity:
-3241.93%
Return On Invested Capital:
-1375.06%
Operating Margin:
-7.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -$598.1M | $1.1B | $996.9M | $269.4M | $232.9M | |
| Gross Profit | -$129.3M | $163.3M | $174.8M | $43M | $50.2M | |
| Operating Income | -$240.5M | -$171.8M | -$107.8M | -$33.7M | -$17.3M | |
| EBITDA | -$242.3M | -$601.3M | -$77.8M | -$468.5M | -$14.3M | |
| Diluted EPS | -$206.41 | -$208.41 | -$51.16 | -$81.03 | -$8.51 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.6B | $2.6B | $1.9B | $589.4M | |
| Total Assets | -- | $3.6B | $4.6B | $2.1B | $696.8M | |
| Current Liabilities | -- | $1.5B | $3.3B | $1.8B | $872.4M | |
| Total Liabilities | -- | $1.6B | $3.3B | $1.9B | $1B | |
| Total Equity | -- | $1.9B | $1.3B | $194.6M | -$312.5M | |
| Total Debt | -- | -- | $303.9M | $353.9M | $120.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$39.3M | -$2.3B | -$430.1M | -$1.7B | -$21.7M | |
| Cash From Investing | -$362.9M | $1.2B | $163.4M | $988.3M | -$51K | |
| Cash From Financing | $1.1B | $211.7M | -$230.4M | $46M | -$13.3M | |
| Free Cash Flow | -$70.6M | -$2.3B | -$431.9M | -$1.7B | -$22.3M | |
NEUE
Sector
Market Cap
$35.7M
$45.6M
Price % of 52-Week High
25.98%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
84.96%
-0.74%
1-Year Price Total Return
-18.06%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.38
200-day SMA
Sell
Level
$5.56
Bollinger Bands (100)
Sell
Level
4.77 - 5.53
Chaikin Money Flow
Sell
Level
-282.8M
20-day SMA
Sell
Level
$4.86
Relative Strength Index (RSI14)
Sell
Level
41.29
ADX Line
Buy
Level
14.86
Williams %R
Neutral
Level
-76.4706
50-day SMA
Sell
Level
$5.06
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-124.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.4636)
Sell
CA Score
(Annual)
Level (-3.2176)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.1199)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeueHealth Inc is a value driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. It also enables independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally.
Stock Forecast FAQ
In the current month, NEUE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NEUE average analyst price target in the past 3 months is --.
-
Where Will NeueHealth Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeueHealth share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About NeueHealth?
Analysts are divided on their view about NeueHealth share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeueHealth is a Sell and believe this share price will drop from its current level to --.
-
What Is NeueHealth's Price Target?
The price target for NeueHealth over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NEUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeueHealth is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NEUE?
You can purchase shares of NeueHealth via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeueHealth shares.
-
What Is The NeueHealth Share Price Today?
NeueHealth was last trading at $7.44 per share. This represents the most recent stock quote for NeueHealth. Yesterday, NeueHealth closed at $4.31 per share.
-
How To Buy NeueHealth Stock Online?
In order to purchase NeueHealth stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 6.55% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.68% over the past day.
